That’s the message in a report out late Thursday from SVB Leerink analyst Daina M. Graybosch, who initiated her coverage of Merck stock (ticker: MRK) at Outperform. She set a price target of $103, pointing to a premium of more than 23% over its Thursday closing price of $83.46 per share.
“We believe investors underappreciate the potential for: long-term, diverse Keytruda revenues… [and] return from MRK’s aggressive strategy to explore... and then pursue... promising Keytruda add-on approaches to extend Keytruda’s competitive moat and lifecycle beyond patentlife,” Graybosch wrote.
【热点资讯】
智能推荐你感兴趣的信息。
【娱乐趣生活】
幸运转盘抽奖,公平公正,更多实物等你来瓜分。
【打工赚算力】
算力决定TLBC的采集速度,拥有的算力值越高,获得TLBC越多,每天完成所有算力活动,还有随机红包奖励哦。
【每天领红包】
每天采集完12次TLBC,有机会获得1元随机红包;每天完成所有算力活动,有机会获得5元随机红包。
【娱乐趣生活】
幸运转盘抽奖,公平公正,更多实物等你来瓜分。
【收TLBC】TLBC是基于个人在陀螺世界活动产生奖励,可以用于APP的消费与兑换等。
【打工赚算力】算力决定TLBC的采集速度,拥有的算力值越高,获得TLBC越多,每天完成所有算力活动,还有随机红包奖励哦。
【养恐龙】拖动合成恐龙,玩法魔性,风格新鲜,越高级恐龙获得的属性和权益越多!「算力龙」、「红包龙」、「分红龙」等你来体验,更多恐龙持续研发中~
Keytruda is a so-called anti-PD(L)1 inhibitor, one of a class of new immunotherapy drugs that uses the patient’s own immune system to fight cancer, and has had a major impact on cancer treatments. Keytruda is currently the top-selling drug of its kind, and Graybosch argued that the drug will maintain its position.
“MRK’s early ‘all-in’ bet and solid clinical and commercial execution established a deep competitive ‘platform-moat,’” she wrote.